All News

NDV-01, a sustained-release intravesical combo, delivered durable 12‑month complete responses in high-risk NMIBC, particularly among patients with BCG-unresponsive disease.

According to Lantheus, Pylarify TruVu is formulated to improve product stability at higher radioactive concentrations, facilitating more efficient manufacturing and distribution.

Sadashiv Bhole, MBBS, MS (Surgery), MCh (Urology), DNB (Genito-Urinary Surgery), FMASI, offers an in-depth perspective on how robotic platforms are being adopted across India.

In this episode of The UroOnc Minute, host Adam B. Weiner, MD, speaks with Christian D. Fankhauser, MD, MPH, about the evolving role of biomarkers in testicular cancer.

A central theme is the widening gap between clinical work and health care policy.

FX-909, a first-in-class PPARγ inverse agonist, demonstrated manageable toxicity and preliminary antitumor activity in patients with advanced urothelial carcinoma.

At SUFU 2026, 24-month data from the TITAN 2 trial showed that the Altaviva ITNM system provided sustained reductions in urgency urinary incontinence episodes, durable quality-of-life improvements, and a favorable safety profile through 24 months.

ImmunityBio plans to submit a biologics license application to the FDA by Q4 of 2026.

The target action date for the application is June 19, 2026.

A recap of the FDA submissions and regulatory decisions in urology from February 2026.

"The CR rates in both arms are compelling, being higher than 50% with both strategies…BI-EFS rates in participants at week 18 CR assessment were comparable between arms and were higher than 80% in both arms," said Andrea Necchi, MD.

"Belzutifan plus lenvatinib addresses an unmet clinical need and represents a potential new treatment option for patients with RCC that progressed after PD 1 or-L1 therapy,” said Robert J. Motzer, MD.

“After 28 months’ follow-up, the combination of pembrolizumab and belzutifan resulted in a statistically significant and clinically meaningful improvement in disease-free survival over pembrolizumab single agent,” said Toni K. Choueiri, MD.

"Tokyo BCG is noninferior to TICE. This means that the BCG shortage could be mitigated with the Tokyo strain," said Robert Svatek, MD, MSCI.

“When we looked at ctDNA dynamics, patients who had baseline and postneoadjuvant ctDNA negativity had the best outcomes," said Pooja Ghatalia, MD.

“Neoadjuvant and adjuvant EV/pembro significantly improved event-free survival, overall survival, and path CR rate vs neoadjuvant gem/cis in patients with muscle-invasive bladder cancer who are eligible for cisplatin-based chemotherapy and radical cystectomy," said Matthew D. Galsky, MD.

“Biochemical responses were seen at all dose levels, with an overall PSA50 response of 62% and a PSA90 response of 40%," according to Fred Saad, CQ, MD, FRCS, FCAHS.

Karim Fizazi, MD, PhD, reported that the 9-year prostate cancer-specific survival rate was 90% (95% CI, 86-94) in patients receiving cabazitaxel vs 89% (95% CI, 84-93) in patients not receiving cabazitaxel.

"Capivasertib in combination with abiraterone represents a potential first-in-class targeted treatment for patients with this now PTEN-defined metastatic APMN,” said Daniel J. George, MD.

"Enzalutamide plus radium-223 is an option in first-line treatment for mCRPC patients with bone metastases," said Enrique Gallardo, MD.

Median OS was 28 months (95% CI, 13-NR) in arm 1, 37 months (95% CI, 26-NR) in arm 2, and 68 months (95% CI, 38-NR) in arm 3.

PROSTOX Standard estimates the risk of late genitourinary toxicity following conventionally fractionated or moderately hypofractionated radiation therapy for localized prostate cancer.

AKY-1189 is currently under investigation in the phase 1b NECTINIUM-2 trial.

Take a look into the top data set to be presented at this year's ASCO GU Cancers Symposium in San Francisco, California.

Data showed that measurement of ctDNA and utDNA could identify patients who are most likely to remain cancer-free following systemic therapy.

The combination of enfortumab vedotin plus pembrolizumab extended event-free and overall survival in patients with MIBC who are ineligible for cisplatin-based chemotherapy.

In this episode, Amy Pearlman, MD, sits down with Alan J. Wein, MD, PhD (hon), FACS, to discuss how the field of urology has evolved and how clinicians can thoughtfully evolve alongside it.